The HIV Nef protein downregulates the cell-surface expression of the HIV receptor glycoprotein CD4, but the significance of this event has remained obscure. Recent data suggest that Nef reduces cell-surface CD4 to promote the efficient spread of the virus.
The human immunodeficiency virus (HIV) Nef protein has a number of apparently independent functions in vitro and has been shown to be absolutely required for viral pathogenesis in vivo. This requirement was first demonstrated by the observation that a mutant form of simian immunodeficiency virus (SIV) that lacked Nef failed to induce disease in macaque monkeys [1] . Further support was provided by data published last year demonstrating that transgenic mice, in which expression of Nef alone (in the absence of other viral gene products) was restricted to CD4-positive cells, exhibited symptoms of AIDS-like pathology [2] . At present, the significance of the various in vitro functions of Nef to the activity of the protein in vivo is the subject of debate. Two papers published in this issue of Current Biology [3, 4] address this topic and provide evidence that downregulation of cell-surface CD4 by Nef is important for the spread of HIV from the infected cell, an observation with clear implications for viral replication in vivo.
More than a decade of research on Nef has defined three main in vitro functions of the protein [5] . Firstly, expression of Nef in productively infected cells enhances the infectivity of HIV particles released from these cells. Nef is a myristoylated protein and a subset of cellular Nef is located at the plasma membrane, thus becoming incorporated into budding virus particles. Virions that contain Nef are able to undergo reverse transcription more efficiently upon entry into the next host cell; although the mechanism for this enhancement is obscure, it has been suggested to involve the recruitment of a kinase to the virus particle. Secondly, Nef has been reported to have diverse effects on cellular signal transduction pathways -there is little general consensus in this area and most experiments have been performed in cells expressing Nef in the absence of other viral proteins and thus the significance for virus replication as a whole remains to be proven. It is clear, however, that Nef interacts with a number of cellular protein kinases, and acts both as a kinase substrate and as a modulator of kinase activity.
Finally, Nef has been demonstrated by many groups to downregulate cell-surface expression of CD4, a phenomenon first observed in 1987 but not studied further until 1993. Studies into the mechanism have demonstrated that Nef binds not only to CD4 [6] but also to components of clathrin-coated pits -the µ chains of adaptor-protein complexes [7] and the catalytic subunit of the vacuolar ATPase (V-ATPase) [8] . The binding of Nef to CD4 is mediated by interactions between the region corresponding to amino acids 61-110 of Nef and a dileucine motif in the cytoplasmic domain of CD4. Residues in an unstructured loop near the carboxyl terminus of Nef, including another dileucine motif and a conserved acidic cluster, mediate binding to the µ chain and to V-ATPase.
These interactions, therefore, suggest that Nef acts as a linker to recruit CD4 into clathrin-coated pits and subsequently accelerate its endocytosis ( Figure 1 ). The endocytosed CD4 accumulates in early endosomes where it is subjected to a sorting process and either recycled to the cell surface or passed to lysosomes for degradation. Nef also appears to affect this sorting by diverting CD4 into the lysosomal pathway, presumably as a result of interactions with the V-ATPase, which is involved in endosome acidification. As an aside, Nef has also been shown to downregulate cell-surface major histocompatibility complex (MHC) class I molecules, although the mechanism of this effect has been reported to be distinct from that involved in CD4 downregulation, because it requires a tyrosine-based endocytosis signal in the MHC class I molecules.
In addition to Nef, two other HIV proteins are involved in decreasing the cell-surface expression of CD4. Interactions between CD4 and the viral envelope glycoprotein gp160 (the product of the env gene that is subsequently cleaved by endoplasmic reticulum/Golgi resident proteases into gp120 and gp41 subunits) during protein synthesis results in the sequestration of the CD4-gp160 complex in the endoplasmic reticulum [9] . As well as reducing cell-surface levels of CD4, clearly this is bad news for the virus as it will prevent migration of gp160 to the plasma membrane where it is needed to take part in the assembly of infectious virus particles, which bud directly from the plasma membrane. HIV type 1 (HIV-1) encodes a small accessory protein Vpu; uniquely the expression of both Vpu and gp160 are coordinated because the genes for these proteins are carried in a bicistronic mRNA molecule. Vpu is an integral membrane phosphoprotein that, like Nef, binds to the cytoplasmic domain of CD4. Vpu then mediates the translocation of CD4 to the cytosol and promotes CD4 degradation by a mechanism that involves the cytosolic ubiquitin-proteasome pathway [10] (Figure 1 ).
So why does HIV have mechanisms for reducing the cellsurface expression of CD4? The two papers [3, 4] published in this issue provide a partial explanation to this conundrum. Ross et al. [3] and Lama et al. [4] show that high levels of CD4 on the cell surface interfere with the production and release of infectious virus particles from the cell. The two groups propose different mechanisms to account for this inhibition, however. Ross et al. [3] demonstrate that high levels of surface CD4 reduce the overall amount of virus released from the cell, but find that the absolute infectivity of released virus is unaffected. In contrast, Lama et al. [4] suggest that, in the presence of high levels of surface CD4, the virus released has a reduced envelope glycoprotein content and is consequently less infectious than virus released from CD4-negative cells. Given that both groups used similar experimental systems, this discrepancy will clearly need to be addressed. At a virological level, however, the implication of the results presented in both of these studies is that the spread of HIV from an infected cell is inhibited by cellsurface CD4. Importantly, both groups [3, 4] show that the CD4-mediated inhibition of the spread of HIV is relieved by expression of Nef, and Lama et al. [4] observe that Vpu can also block this inhibition.
There are two reasons why the virus should need Nef as well as Vpu and gp160 for CD4 downregulation. Although Vpu and gp160 will interfere with the fate of newly synthesised CD4, they will have no effect on the pre-existing levels of cell-surface CD4. Neither will they affect the fate of CD4 that is recycled from endosomes back to the cell surface. Furthermore, in T cells CD4 is stabilised at the cell surface by an interaction between its cytoplasmic domain and the Src-family tyrosine kinase Lck and this stabilisation prevents CD4 from associating with clathrin-coated pits, meaning that HIV needs a mechanism to actively promote CD4 endocytosis. Also, Nef has been shown to be expressed at high levels early in the virus replication cycle, before the expression of Env and Vpu. Thus, we can envision a scenario in which early expression of Nef results in a dramatic reduction in the levels of cell-surface CD4. The subsequent lack of CD4 at the cell surface allows the successful assembly of HIV virion particles.
There are two other possible reasons why Nef-mediated CD4 downregulation might be beneficial to the virus. Firstly, it could inhibit reinfection by more HIV particles. Downregulation of CD4 by SIV Nef has been shown to prevent subsequent infection of human T cells with HIV-1, and there is evidence from in vitro studies that reinfection of HIV-infected T cells results in the accumulation of viral DNA but does not augment production of virus particles. Presumably this is because reinfection effectively 'overloads' the biosynthetic capability of the cell. Although this is unlikely to be relevant in the periphery in vivo, it R460 Current Biology, Vol 9 No 12
Figure 1
HIV uses multiple mechanisms for reducing the cell-surface levels of CD4. At the plasma membrane, Nef interacts with both the cytoplasmic domain of cell-surface CD4 and components of clathrin-coated pits, thus recruiting CD4 into the endocytic pathway. Instead of recycling from early endosomes to the cell surface, CD4 is sorted into lysosomes for degradation. Newly synthesised CD4 and HIV Env gp120 and gp41 proteins associate in the endoplasmic reticulum where the complex is sequestered. Vpu interacts with the cytoplasmic domain of CD4 in the endoplasmic reticulum and mediates translocation of CD4 into the cytosol, CD4 ubiquitination and targeting of CD4 to proteasomes. Env is then free to be exported to the cell surface. may be important in HIV-infected lymph nodes where there are likely to be high levels of virus.
Secondly, there is evidence that signals transduced through the cytoplasmic domain of CD4 can result in the inhibition of transcription mediated by the HIV long terminal repeat, which is the promoter for the viral genes [11] . These signals were induced in vitro by the binding of monoclonal antibodies to a specific extracellular region, the immunoglobulin complementarity determining region 3 (CDR3)-like region of CD4, but not to the CDR2-like region of CD4, which is also located in the amino-terminal (D1) extracellular domain of CD4. It is possible, however, that similar signals might be induced in vivo by the binding of the physiological CD4 ligand, interleukin-16 (IL-16), to the CDR3-like region. IL-16 induces CD4 clustering and subsequent signalling events, including a rise in the levels of intracellular calcium and inositol (1,4,5)-trisphosphate [12] . Intriguingly, the CDR3 region of CD4 has been reported to be involved in CD4 dimerisation. Presumably, one effect of Nef-mediated CD4 downregulation would be to prevent the transduction of these signals that negatively regulate HIV transcription and concomitant virus production. Clearly this effect of Nef would be important early in the virus replication cycle. So, although Ross et al. [3] and Lama et al. [4] demonstrate an important consequence of Nef-mediated CD4 downregulation in terms of viral transmission, the other potential consequences of CD4 downregulation merit further investigation.
These two new papers raise a critical issue, however, that should be a priority for future research. The results should be extended either to transformed T-cell lines or preferably to primary lymphocytes in order to confirm the in vivo relevance of this phenomenon at CD4 expression levels that accurately reflect the physiological levels found on the HIV-infected host cell. Furthermore, in a broader context Nef represents a good example of how viruses have evolved to cope with a limited set of genes by producing proteins that have a wide variety of functions. Although light has now been shed on the biological significance of one of the in vitro functions of Nef, the challenge now is to determine whether other in vitro functions of the protein are also important for Nef action in vivo. If they are, the race will be on to develop new chemotherapeutic agents to fight HIV that are targeted against Nef function.
